Alpha-Antitrypsin Deficiency Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Alpha-Antitrypsin Deficiency - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Alpha-Antitrypsin Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alpha-Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha-Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha-Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha-Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Alpha-Antitrypsin Deficiency - Overview
3. Alpha-Antitrypsin Deficiency - Therapeutics Development
4. Pipeline Overview
5. Pipeline by Companies
6. Pipeline by Universities/Institutes
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Alpha-Antitrypsin Deficiency - Therapeutics Assessment
10. Assessment by Target
11. Assessment by Mechanism of Action
12. Assessment by Route of Administration
13. Assessment by Molecule Type
14. Alpha-Antitrypsin Deficiency - Companies Involved in Therapeutics Development

• Adverum Biotechnologies Inc
• Alnylam Pharmaceuticals Inc
• Applied Genetic Technologies Corp
• Arrowhead Pharmaceuticals Inc
• Carolus Therapeutics Inc
• Cevec Pharmaceuticals GmbH
• Editas Medicine Inc
• Grifols SA
• Inhibrx LP
• Intellia Therapeutics Inc
• International Stem Cell Corp
• Kamada Ltd
• OncBioMune Pharmaceuticals Inc
• Polyphor Ltd
• ProMetic Life Sciences Inc
• rEVO Biologics Inc
• Z Factor Ltd

For more information about this report visit https://www.researchandmarkets.com/research/9fclpr/alphaantitrypsin